Mylan immune to outbreak of 'pollution' closure notices served to Indian firms
This article was originally published in Scrip
Over a dozen pharmaceutical manufacturing units in the southern Indian state of Andhra Pradesh, including those of the local firms, Hetero Drugs and Aurobindo Pharma, and the multinational, Mylan, have been pulled up for allegedly violating pollution norms. But Mylan says its commercial operations are unaffected.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.